Netherlands-based molecular testing firm Qiagen has signed an agreement to acquire all shares of Spanish diagnostics maker STAT-Dx for a cash consideration of around $147m.

Under the terms of the agreement, STAT-Dx is eligible for an additional $44m of regulatory and commercial milestone payments from Qiagen.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Through this deal, Qiagen will obtain ownership of STAT-Dx’s system designed for fully integrated molecular analysis for oncology and to diagnose common disorders such as serious respiratory or gastrointestinal infections.

Based on real-time polymerase chain reaction (PCR) and the firm’s DiagCORE technologies, the system can be used to simultaneously carry out sample-to-insight processing of up to 48 molecular targets.

The system delivers both qualitative and quantitative insights into the accurate cause of a syndrome within approximately one hour.

It uses single-use cartridges that feature Qiagen’s sample and assay technologies developed as part of an alliance between the firms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The system is designed for significantly more cost-efficient test processing as required by the current reimbursement environment.”

The system can run any type of clinical sample such as pathological tissue samples, liquid samples, or sputum samples in infectious disease, and facilitates direct on-board swab processing.

Qiagen CEO Peer Schatz said: “The system is designed for significantly more cost-efficient test processing as required by the current reimbursement environment.

“Additional application areas for this system include companion diagnostics, quantitative analysis and immunoassay tests, offering customers a new level of flexibility and accurate diagnosis designed to support better outcomes for patients and healthcare systems.”

The system, which obtained CE-IVD marking this month, will be branded as QIAstat-Dx following the closure of the acquisition in the second quarter of 2018.

Qiagen expects the system to generate around $7m this year and a minimum of $30m next year.